RCAMU
HZNP

Rothschild & Co Asset Management US’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Rothschild & Co Asset Management US’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$45.9M Sell
403,734
-24,972
-6% -$2.07M 0.7% 49
2022
Q3 		$26.5M Sell
428,706
-13,725
-3% -$959K 0.45% 66
2022
Q2 		$35.3M Buy
442,431
+20,248
+5% +$1.92M 0.54% 54
2022
Q1 		$44.4M Buy
422,183
+156,549
+59% +$15.3M 0.57% 51
2021
Q4 		$28.6M Sell
265,634
-2,728
-1% -$298K 0.34% 73
2021
Q3 		$29.4M Sell
268,362
-18,401
-6% -$1.91M 0.36% 66
2021
Q2 		$26.9M Sell
286,763
-142,901
-33% -$13.2M 0.32% 82
2021
Q1 		$39.5M Sell
429,664
-176,681
-29% -$14.9M 0.49% 54
2020
Q4 		$44.4M Sell
606,345
-129,104
-18% -$9.6M 0.57% 49
2020
Q3 		$57.1M Sell
735,449
-162,964
-18% -$11.2M 1.03% 10
2020
Q2 		$49.9M Sell
898,413
-537,821
-37% -$23M 0.74% 26
2020
Q1 		$42.5M Sell
1,436,234
-268,367
-16% -$9.08M 0.66% 36
2019
Q4 		$61.7M Sell
1,704,601
-166,811
-9% -$5.11M 0.64% 29
2019
Q3 		$51M Buy
1,871,412
+173,738
+10% +$4.49M 0.55% 37
2019
Q2 		$40.8M Buy
1,697,674
+83,247
+5% +$2.11M 0.44% 77
2019
Q1 		$42.7M Sell
1,614,427
-47,923
-3% -$1.14M 0.46% 69
2018
Q4 		$32.5M Buy
1,662,350
+10,573
+0.6% +$207K 0.39% 81
2018
Q3 		$32.3M Sell
1,651,777
-29,414
-2% -$559K 0.33% 116
2018
Q2 		$27.8M Sell
1,681,191
-14,369
-0.8% -$219K 0.3% 145
2018
Q1 		$24.1M Sell
1,695,560
-48,035
-3% -$710K 0.27% 157
2017
Q4 		$25.5M Sell
1,743,595
-63,534
-4% -$892K 0.27% 158
2017
Q3 		$22.9M Buy
1,807,129
+330,424
+22% +$4.2M 0.25% 170
2017
Q2 		$17.5M Buy
1,476,705
+265,013
+22% +$3.3M 0.2% 194
2017
Q1 		$17.9M Buy
1,211,692
+11,189
+0.9% +$181K 0.21% 194
2016
Q4 		$19.4M Buy
1,200,503
+287,373
+31% +$5.21M 0.25% 163
2016
Q3 		$16.6M Buy
913,130
+395,830
+77% +$7.73M 0.28% 146
2016
Q2 		$8.52M Buy
517,300
+87,875
+20% +$1.42M 0.15% 220
2016
Q1 		$7.12M Buy
429,425
+7,351
+2% +$129K 0.13% 227
2015
Q4 		$9.15M Sell
422,074
-9,965
-2% -$194K 0.17% 198
2015
Q3 		$8.56M Sell
432,039
-21,331
-5% -$674K 0.17% 202
2015
Q2 		$15.8M Buy
+453,370
New +$13.8M 0.29% 117

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Rothschild & Co Asset Management US's HZNP Position: Q4 2022 in Review

Rothschild & Co Asset Management US reduced its Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) stake by 5.8% in Q4 2022, selling an estimated $2.07M and leaving 403,734 shares worth $45.9M. The position accounts for 0.7% of the portfolio, ranked #49.

Rothschild & Co Asset Management US first reported a position in HZNP in Q2 2015 and has held it in 31 quarters since. The position peaked at $61.7M in Q4 2019. 615 funds tracked by Wall St. Rank hold HZNP as of Q4 2022.

  • Rothschild & Co Asset Management US held 403,734 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $45.9M as of Q4 2022.
  • Rothschild & Co Asset Management US sold 24,972 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2022, an estimated $2.07M.
  • Horizon Therapeutics Public Limited Company Ordinary Shares made up 0.7% of Rothschild & Co Asset Management US's portfolio in Q4 2022, its #49 holding.
  • Rothschild & Co Asset Management US first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2015 and has held it in 31 quarters since.
  • Rothschild & Co Asset Management US's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $61.7M in Q4 2019.
  • 615 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2022.

Based on Rothschild & Co Asset Management US's 13F filing for Q4 2022, filed 14 Feb 2023.